Vaccines for Category A bioterrorism diseases

Bibliography

• ALIBEK K, HANDELMAN S: Biohazard: The Chilling True Story of the Largest Covert Biological Weapons Program in the World. Random House, New York, USA (1999).
   Google Scholar
• INGLESBY TV, O& TOOLE T, HENDERSON DA et al: Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA (2002) 287:2236–2252.
   PubMed Web of Science ®Google Scholar
• ••An excellent review of aspects of anthrax asit would present as a cause of biological warfare. Rewritten after the post September 11 US mail outbreak.
   Google Scholar
• CENTERS FOR DISEASE CONTROL AND PREVENTION: Update: investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001. Morbid. Mortal. Week. Rep. MMWR. (2001) 50:909–919.
   PubMedGoogle Scholar
• MESELSON M, GUILLEMIN J, HUGH-JONES M et al.: The Sverdlovsk anthrax outbreak of 1979. Science (1994) 266:1202–1208.
   PubMed Web of Science ®Google Scholar
• JERNIGAN JA, STEPHENS DS, ASHFORD DA et al.: Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Einerg. Infect. Dis. (2001) 7:933–944.
   PubMed Web of Science ®Google Scholar
• CIESLAK T, CHRISTOPHER GW, KOTEPETER MG et al.: Immunization against potential biological warfare agents. Clin. Infect. Dis. (2000) 30:843–850.
   PubMed Web of Science ®Google Scholar
• BRACHMAN PS, FRIEDLANDER AM: Anthrax. In, Vaccines (Plotkin SA, Orenstein WA, eds) 3rd ed., WB Saunders, Philadelphia, USA (1999), 629–637.
   Google Scholar
• CENTERS FOR DISEASE CONTROL AND PREVENTION: Use of anthrax vaccine in the United States. Recommendations of the Advisory Committee on Immunization Practices. Morbid Mortal. Week. Rep. MMWR (2000) 49 (RR-15):1–20.
   Google Scholar
• ••The most up-to-date ACIP overview of thecurrently available US anthrax vaccine.
   Google Scholar
• BRACHMAN PS, GOLD H, PLOTKIN SAet al.: Field evaluation of a human anthrax vaccine. Ain. J. Public Health (1962) 52:632–645.
   Web of Science ®Google Scholar
• CHEN RT, RASTOGI SC, MULLEN JRet al.: The Vaccine Adverse Event Reporting System (VAERS). Vaccine (1994) 12:542–550.
   Google Scholar
• NASS M: Anthrax vaccine. Model of a response to the biologic warfare threat. Infect. Dis. Clin. North Ain. (1999) 187:187–208.
   Google Scholar
• PITTMAN PR, KIM-AHN G, PIFAT DY et al.: Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans. Vaccine (2002) 20:1412–1420.
   PubMed Web of Science ®Google Scholar
• IVINS B, FELLOW P, PITT L et al: Experimental anthrax vaccine: efficacy of adjuvant combined with protective antigen against aerosol Bacillus antbracis spore challenge in guinea pigs. Vaccine (1995) 13:1779–1784.
   PubMed Web of Science ®Google Scholar
• KOBILER D, GOZES Y, ROSENBERG H et al.: Efficacy of protection of guinea pigs against infection with Bacillus anthracis spores by passive immunization. Infect. Inman. (2002) 70:544–560.
   PubMed Web of Science ®Google Scholar
• CASADEVALL A: Passive antibody administration (immediate immunity) as a specific defense against biological weapons. Emerg. Infect. Dis. (2002) 8:831-841. Available from URL:http://www.cdc.gov/ ncidod/EID/vol8no8/01-0516.htm. (Cited 1 July 2002).
   Google Scholar
• FLICK-SMITH HC, WALKER NJ, GIBSON P et al.: A recombinant carboxy-terminal domain of the protective antigen of Bacillus anthracisprotects against anthrax infection. Infect. Immun. (2002) 70:1653–1656.
   PubMed Web of Science ®Google Scholar
• PRICE BM, LINER AL, PARKS et al: Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein. Infect. Immun. (2001) 69:4509–4515.
   PubMed Web of Science ®Google Scholar
• •An example of the use of DNA (genetic or genomic) immunisation to prevent a biological warfare disease, in this case anthrax.
   Google Scholar
• FLICK-SMITH HC, EYLES JE, HEBDON R et al.: Mucosal or parenteral administration of microsphere-associated Bacillus anthracisprotective antigen protects against anthrax infection in mice. Infect. Immun. (2002) 70:2022–2028.
   PubMed Web of Science ®Google Scholar
• •An example of the use of bioabsorbable microsphere technology to produce a mucosal immunogen to prevent anthrax.
   Google Scholar
• BROSSIER FE LEVY M, MOCK M: Anthrax spores make an essential contribution to vaccine efficacy. Infect. Immun. (2002) 70:661–664.
   PubMed Web of Science ®Google Scholar
• HENDERSON DA, INGLESBY TV, BARTLETT JG et al.: Smallpox as a biological weapon. Medical and public health management. JAMA. (1999) 281:2127–2137.
   Google Scholar
• ••An excellent review of smallpox as it couldbe utilised as a biological warfare agent.
   Google Scholar
• HENDERSON DA: Smallpox: clinical and epidemiologic features. Emerg. Infect. Dis. (1999) 5:537–539.
   PubMed Web of Science ®Google Scholar
• WORLD HEALTH ORGANIZATION: Declaration of global eradication of smallpox. Wkly Epidemic]. Rec. (1980) 55:145–152.
   Google Scholar
• CENTERS FOR DISEASE CONTROL AND PREVENTION: Vaccinia (smallpox) vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001. (2001) 50(RR-10):1–25.
   Google Scholar
• ••The latest AC1P guidelines related to thesmallpox (vaccinia) vaccine with discussions on the potential for new immunogens and strategies for use in a bioterrorist setting.
   Google Scholar
• DEMKOWICZ WE, LITTAUA RA, WANG J, ENNIS FA: Human cytotoxic T-cell memory: long-lived responses to vaccinia virus.Vim/. (1996)70:2627–2631.
   Web of Science ®Google Scholar
• EL-AD B, ROTH Y, WINDER A et al: The persistence of neutralizing antibodies after revaccination against smallpox. J. Infect. Dis. (1990) 161:446–448.
   PubMed Web of Science ®Google Scholar
• MACK TM: Smallpox in Europe, 1950-1971. J. Infect. Dis. (1972) 125:161–169.
   PubMed Web of Science ®Google Scholar
• ROSENTHAL SR, MERCHLINSKY M, KLEPPINGER C, GOLDENTHAL KL: Developing new smallpox vaccines. Emerg. Infect. Dis. (2001) 7:920–926.
   PubMed Web of Science ®Google Scholar
• REDFIELD RR, WRIGHT DC, JAMES WD et al.: Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N. Engl. J. Med. (1987) 316:673–676.
   PubMed Web of Science ®Google Scholar
• GURVICH EB: The age-dependent risk of postvaccination complications in vaccines with smallpox vaccine. Vaccine. (1992) 10:96–97.
   PubMed Web of Science ®Google Scholar
• DE VRIES E: Post-vaccinal perivenous encephalitis. Elsevier, Amsterdam, Holland, 1960.
   Google Scholar
• LANE JM, RUBEN FL, NEFF JM, MILLAR JD: Complications of smallpox vaccination, 1968: national surveillance in the United States. N Engl. J. Med. (1969) 281:1201–1208.
   PubMed Web of Science ®Google Scholar
• FREY SE, COUCH RB, TACKET CO et al.: Clinical responses to undiluted and diluted smallpox vaccine. N Engl. J. Med. (2002) 346:1265–1274.
   PubMed Web of Science ®Google Scholar
• •A well done study investigating the utility of dilution of the smallpox vaccine to allow potential immunisation of a larger number of susceptibles.
   Google Scholar
• FREY SE, NEWMAN FK, CRUZ J et al:Dose-related effects of smallpox vaccine.N. Engl. J. Med. (2002) 346:1275–1280.
   PubMed Web of Science ®Google Scholar
• •The parallel study of reference 32 which looks into the humoral and cellular responses to immunisation of the diluted vaccinia vaccine.
   Google Scholar
• SUGIMOTO M, YAMANOUCHI K: Characteristics of an attenuated vaccinia virus strain, LM16m0 and its recombinant virus vaccines. Vaccine (1994) 12:675–681.
   PubMed Web of Science ®Google Scholar
• SUTTER G, MOSS B: Novel vaccinia vector derived from the host range restricted and highly attenuated MVA strain ofvaccinia virus. Dev. Biol. Stand. (1995) 84:195–200.
   PubMedGoogle Scholar
• MAYR A: [Historical review of smallpox,the eradication of smallpox and the attenuated smallpox MVA vaccine]. Berlin. Munch. Tierarz. Wahens. (1999) 112:322–328.
   PubMed Web of Science ®Google Scholar
• DENNIS DT, INGLESBY TV, HENDERSON DA et al.: Tularemia as a biological weapon: medical and public health management. JAMA (2001) 285:2763–2773.
   PubMed Web of Science ®Google Scholar
• ••An excellent review on the potential use oftularaemia in the setting of biological warfare.
   Google Scholar
• FELDMAN KA, ENSORE RE, LATHROP SL et al: An outbreak of primary pneumonic tularemia on Martha's Vineyard. N Engl. J. Med. (2001) 345:1601–1606.
   PubMed Web of Science ®Google Scholar
• BELDING DL, MERRILL B: Tularemia in imported rabbits in Massachusetts. N Engl. J. Med. (1941) 224:1085–1087.
   Google Scholar
• LUTWICK LI: ProMED-mail.Tularemia - USA (New York City): RFI. ProMED -mail(1998) 24 Jul: 19980724.1405. http://www.promedmail.org(Accessed 9 July 2002).
   Google Scholar
• TIGERTT WD: Soviet viable Pasteurella tularensis vaccines. Bacteria Rev (1962) 26:354–373.
   PubMedGoogle Scholar
• NIERENGARTEN MB, LUTWICK LI: Developing new tularemia vaccines. Medscape Infectious Diseases (2002) 4(1) http://www.medscape.com/viewarticle/ 431539_print (Accessed 1 July 2002).
   Google Scholar
• SANDSTROM G: The tularemia vaccine. J. Chem. Techna Bictechna (1994) 59:315–320.
   PubMed Web of Science ®Google Scholar
• ••One of the best reviews regarding what isunderstood about the vaccine to prevent tularaemia.
   Google Scholar
• BURKE DS: Immunization against tularemia: analysis of the effectiveness of the live Francisella tularensis vaccine in prevention of laboratory-acquired tularemia. J. Infect. Dis. (1977) 135:55–60.
   PubMed Web of Science ®Google Scholar
• DRABICK JJ, NARAYANAN RB, WILLIAMS JC et al.: Passive protection of mice against lethal Francisella tularensis (live tularemia vaccine strain) infection by the sera of human recipients of the live tularemia vaccine. Am. J. Med. Sd. (1994) 308:83–87.
   PubMed Web of Science ®Google Scholar
• FULOP M, MASTROENI P, GREEN M, TITBALL RW: Role of antibody to lipopolysaccharide in protection againstlow- and high-virulence strains of Francisella tularensis. Vaccine (2002) 19:4465–4472.
   Web of Science ®Google Scholar
• SJOSTEDT A, ANDSTROM G, TARNVIK A: Humoral and cell-mediated immunity in mice to a 174dlodalton lipoprotein of Francisella tularensisexpressed in Salmonella ophimurium. Infect. Immun. (1992) 60:2855–2862.
   PubMed Web of Science ®Google Scholar
• WERNER SB, WEIDMER CE, NELSON BC et al.: Primary plague pneumonia contracted from a domestic cat at South Lake Tahoe, Calif. JAMA. (1984) 251:929–931.
   PubMed Web of Science ®Google Scholar
• INGLESBY TV, DENNIS DT, HENDERSON DA et al: Plague as a biological weapon. Medical and public health management. JAMA (2000) 283:2281–2290.
   Google Scholar
• ••An excellent review on plague as apotential biowarfare agent.
   Google Scholar
• HARRIS S: Japanese biological warfare research on humans: a case study of microbiology and ethics. Ann. NY Acad. Sci. (1992) 555:21–52.
   Google Scholar
• CENTERS FOR DISEASE CONTROL AND PREVENTION: Prevention of plague: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morbid. Mortal. Week. Rep. (1996) 45(RR-14):1–15.
   Google Scholar
• ••The latest ACIP document on theprevention of plague, including a discussion on the inactivated whole-cell plague vaccine that was available in the US.
   Google Scholar
• CAVANAUGH DC, ELISBERG BL, LLEWELLYN CH et al.: Plague immunization. V Indirect evidence for the efficacy of plague vaccine. J. Infect. Dis (1974) 129 (Suppl.):S37–S40.
   Google Scholar
• MEYER KF, CAVANAUGH DC, BARTELLONI PJ, MARSHALL JD: Plague immunization. I. Past and present trends. J. Infect. Dis. (1974) 129(Suppl.):S13–S18.
   Google Scholar
• •A well organised and thoroughly referenced review on the history of vaccines against Yersinia pestis.
   Google Scholar
• MARSHALL JD, BARTELLONI PJ, CAVANAUGH DC et al.: Plague immunization. II. Relation of adverse clinical reactions to multiple immunizations with killed vaccine. J. Infect. Dis. (1974) 129 (Suppl.):S19–S25.
   Google Scholar
• LEARY SE, WILLIAMSON ED, GRIFFIN KF et al. Active immunization with recombinant V antigen from Yersiniapestisprotects mice against plague. Infect. Immun. (1995) 63:2854–2858.
   PubMed Web of Science ®Google Scholar
• ANDREW GP, HEATH DG, ANDERSON GW et al.: Fraction 1 capsular antigen (F1) purification from Yersinia pestis C092 and from an Escherichia colirecombinant strain and efficacy against lethal plague challenge. Infect Inman. (1996) 64:2180–2187.
   PubMed Web of Science ®Google Scholar
• ANDERSON GW, HEATH DG, BOLT CR et al.: Short- and long-term efficacy of single-dose subunit vaccines against Yersinia pestisin mice. Am. J. Trop. Med. Hyg. (1998) 58:793–799.
   PubMed Web of Science ®Google Scholar
• WILLIAMSON ED, ELEY SM,STAGG AJ et al.: A single dose sub-unit vaccine protects against pneumonic plague. Vaccine (2000) 19:566–571.
   Google Scholar
• •An example of the kind of multiple target subunit vaccine that could be a prototype for a highly protective irnmunogen with a low side effect profile.
   Google Scholar
• HEATH DG, ANDERSON GW, MAURO JM et al.: Protection against experimental bubonic and pneumonic plague by a recombinant capsular Fl-V antigen fusion protein vaccine. Vaccine (1998) 16:1131–1137.
   PubMed Web of Science ®Google Scholar
• EYLES JE, SPIERS ID,WILLIAMSON ED, ALPAR HO: Analysis of local and systemic immunological responses after intra-tracheal, intra-nasal and intra-muscular administration of microspheres co-encapsulated Yersinia pestis sub-unit vaccines. Vaccine (1998) 16:2000–2009.
   PubMed Web of Science ®Google Scholar
• •Another example of the use of mucosal immunisation using biodegradable microspheres containing target antigens that has great potential in the future field of vaccinology.
   Google Scholar
• LEARY SE, GRIFFIN KF, GARMORY HS et al.: Expression of an RN fusion protein in attenuated Salmonella typhimurium and protection of mice against plague. Microbial. Pathogen. (1997) 23:167–179.
   PubMed Web of Science ®Google Scholar
• ARNON SS, SCHECHTER R, INGLESBY TV et al: Botulism as a biological weapon. Medical and public health management. JAMA (2001) 285:1059–1070.
   Google Scholar
• ••An excellent review on the possibility ofbotulinum toxin being utilised as an agent of biological warfare.
   Google Scholar
• BYRNE MP, SMITH LA: Development of vaccines for the prevention of botulism. Biochimie. (2000) 82:955–966.
   PubMed Web of Science ®Google Scholar
• CLAYTON MA, CLAYTON JM, BROWN DR, MIDDLEBROOK JL: Protective vaccination with a recombinant fragment of Clostridium botulinum neurotwdn serotype A expressed from a synthetic gene in Escherichia coli Infect. Immun. (1995) 63:2738–2742.
   Google Scholar
• ROCKE TE, SAMUEL MD, SWIFT PK, YARRIS GS: Efficacy of a type C botulism vaccine in green-winged teal.Dis.(2000) 36:489–493.
   Google Scholar
• BYRNE MP, SMITH TJ,MONTGOMERY VA, SMITH LA: Purification, potency, and efficacy of the botulinum neurotwdn type A binding domain from Pichia pastoris as a recombinant vaccine candidate. Infect. Immun. (1998) 66:4817–4822.
   PubMed Web of Science ®Google Scholar
• CLAYTON J, MIDDLEBROOK JK: Vaccination of mice with DNA encoding a large fragment of botulinum neurotwdn serotype A. Vaccine. (2000) 18:1855–1862.
   PubMed Web of Science ®Google Scholar
• LEE JS, PUSHKO P, PARKER MD et al: Candidate vaccine against botulinum neurotwdn serotype A derived from a Venezuelan equine encephalitis vector system. Infect. Immun. (2001) 69:5709–5715.
   PubMed Web of Science ®Google Scholar
• •This study illustrates the use of the Venezuelan encephalitis vector system as an example of a chimeric agent without replicative potential as an irnmunogen, in this case for type A botulism.
   Google Scholar
• WU HC, YEH CT, HUANG YL et al.:Characterization of neutralizing antibodies and identification of neutralizing epitope mimics on the Clostridium botulinum neurotwdn type A. Appl. Environ. Microbial. (2001) 67:3201–3207.
   PubMed Web of Science ®Google Scholar
• http://www.hopkins-biodefense.org
   Google Scholar
• Johns Hopkins Center for Biodefense website.
   Google Scholar